This structure is a promising target for cancer therapy because it regulates the crucial process of proteasome-mediated protein degradation, which involves many proteins such as cyclins, caspases, Bcl-2 and the nuclear factor of κB (NF-κB) [2,4]. The gene discussed is BCL2; the disease is cancer.